Vijaya Galic, MD
Gynecologic Oncology · Gainesville, GANPI 1801093513
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,850 of the $34,673 with a category attached, or 80.3%. GSK accounts for 96.7% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $19,034 and has fallen 99.8% since, to $31 in 2025.
Across 62 payments — averaging $559.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$34K
- Merck$282
- Amgen$154
- Takeda Pharmaceuticals U.S.A., Inc.$150
- Eisai Inc.$125
- Tesaro, Inc.$124
- plus $299 from 7 others
What the payments were for
- Speaking & faculty fees$27,85080%
- Travel & lodging$5,20915%
- Food & beverage$1,6145%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 34 | $33,540 |
| Merck | 5 | $282 |
| Amgen | 3 | $154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $150 |
| Eisai Inc. | 1 | $125 |
| Tesaro, Inc. | 3 | $124 |
| AstraZeneca(2 entities) | 3 | $73 |
| Smith+Nephew | 2 | $66 |
| Ipsen Biopharmaceuticals, Inc | 3 | $55 |
| Tersera Therapeutics LLC | 3 | $45 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,673 in reported general payments places this provider in the 85th percentile of 49 gynecologic oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 15 | $9,457 |
| Oxycodone Hcl | 14 | $102 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Gainesville
- Chelesa ChandlerGainesville$3K
- Taylor RivesGainesville$2K
- James BurkeSavannah$276K
- Benedict BenignoAtlanta$273K
- Sharad GhamandeAugusta$214K
- Ruchi GargNewnan$125K
- Adam PyrzakAtlanta$116K
- Gerald FeuerAtlanta$102K
- Margarett EllisonMoultrie$81K
- Guilherme CantuariaAtlanta$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.